Effects of para-chlorophenylalanine on amphetamine and haloperidol-induced changes in striatal dopamine turnover.
Para-chlorophenylalanine (PCPA) was administered to rats, and the animals were sacrificed 48 h later. Animals received various doses of S(+)-amphetamine (AMPH) 31 min before sacrifice or of haloperidol (HAL) 46 min before sacrifice and an intracerebral injection of [3H]tyrosine 15 min prior to sacrifice. PCPA pretreatment potentiated the increased accumulation of striatal [3H]dopamine (DA) induced by doses of AMPH to 1.5 mg/kg, and inhibited the decrease in striatal [3H]DA accumulation observed at higher doses (greater than 2.5 mg/kg) of AMPH. Further, the AMPH-induced increase in endogenous levels of striatal DA was inhibited by PCPA pretreatment. Similarly, PCPA pretreatment potentiated the HAL-induced increase in striatal [3H]DA accumulation. The data are discussed with respect to an inhibitory serotonergic influence on nigrostriatal DA function, and the relationship of nigrostriatal biochemical events to AMPH-induced behavioral changes.
D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D010134:Fenclonine / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009434:Neural Pathways / Q000187:drug effects; D011292:Premedication; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D013378:Substantia Nigra / Q000187:drug effects; D014443:Tyrosine / Q000378:metabolism
D011954:Receptors, Dopamine; D014443:Tyrosine; D000661:Amphetamine; D006220:Haloperidol; D010134:Fenclonine; D004298:Dopamine